rosiglitazone has been researched along with cysteine in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Game, BA; Huang, Y; Lopes-Virella, MF; Xu, M | 1 |
| Bhalla, K; Choi, JH; Dewi, R; Girnun, GD; Hwang, BJ; Mclenithan, J; Ou, L; Pozharski, E; Stock, J; Twaddel, W | 1 |
1 review(s) available for rosiglitazone and cysteine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for rosiglitazone and cysteine
| Article | Year |
|---|---|
Regulation of MMP-1 expression in vascular endothelial cells by insulin sensitizing thiazolidinediones.
Topics: Cells, Cultured; Chromans; Cysteine; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Eukaryotic Initiation Factors; Humans; Hypoglycemic Agents; Immunoblotting; Matrix Metalloproteinase 1; Matrix Metalloproteinase 2; Methionine; Pioglitazone; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Troglitazone; Umbilical Veins | 2003 |
N-Acetylfarnesylcysteine is a novel class of peroxisome proliferator-activated receptor γ ligand with partial and full agonist activity in vitro and in vivo.
Topics: 3T3-L1 Cells; Acetylcysteine; Animals; Cysteine; Diabetes Mellitus, Type 2; Glucose; Homeostasis; Hypoglycemic Agents; Ligands; Mice; Mice, Knockout; PPAR gamma; Protein Binding; Rosiglitazone; Thiazolidinediones | 2011 |